文献速递治疗药物监测与药物基因组学

基于群体药代动力学的双分析物测谎仪:提升用药依从性检测

Blood Never Lies: The PopPK-Based Lie Detector.
PubMed 文献 · Clin Pharmacokinet · 2026-06-16

该研究提出一种基于群体药代动力学的双分析物方法,利用螺内酯及其代谢物坎利酮的独特药代动力学特征,通过模拟虚拟患者和改良Metropolis-Hastings算法联合估计个体参数与给药模式,推断每日服药片数的概率并量化依从性。结果表明,双分析物联合检测较单一分析物更能识别近期漏服,谷浓度优于峰浓度,尤其当患者未额外补服时。

要点

  • 双分析物(原药+代谢物)群体药代动力学模型可提升漏服检测,尤其近期漏服。
  • 谷浓度检测非依从性优于峰浓度,患者未补服时差异更明显。
  • 该方法可推断每日服药0、1或2片的概率,并给出后验依从概率。

核心结论

  • 基于原药与代谢物的双分析物概率性群体药代动力学方法能增强非依从性检测,并可适配其他具有独特药代特征且模型变异低的场景。

研究设计与样本

  • 文献综述筛选出螺内酯及其代谢物坎利酮作为合适候选,基于长期使用和可获取的群体药代动力学模型。
  • 在稳态假设下模拟虚拟患者,并设置多种依从性场景,采用改良Metropolis-Hastings算法联合估计个体药代参数与给药模式。
  • 通过分析模拟的药物和代谢物浓度,推断每日服用0、1或2片的概率,并由后验分布推导后验依从概率。
  • 采用受试者工作特征分析评估诊断性能。

主要发现

  • 原药与代谢物联合使用较任一单独使用改善了非依从性检测,尤其对近期漏服。
  • 谷浓度优于峰浓度,尤其在患者未通过额外服药补偿时。

临床怎么用

  • 临床可考虑利用原药与代谢物的群体药代动力学模型联合评估长期口服药物的依从性,尤其关注谷浓度。

局限性

  • 方法基于模拟虚拟患者和稳态假设,尚未在真实患者中验证。
  • 适用性需满足原药与代谢物具有独特药代特征且模型变异低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Accurate assessment of drug adherence is essential for long-term oral therapies, where self-administration is unsupervised. Conventional tools such as self-reports, electronic monitors, and even therapeutic drug monitoring often fail to detect non-adherence. Population pharmacokinetic modeling improves objectivity but typically relies on a single analyte, which may still miss hidden non-adherence. We propose a bi-analyte population pharmacokinetic-based approach that uses both the parent drug and a metabolite with distinct pharmacokinetics to enhance adherence detection and reconstruct likely dosing histories. METHODS: A literature review identified spironolactone and its metabolite canrenone as suitable candidates, based on long-term use and an available population pharmacokinetic model capturing distinct elimination profiles. Virtual patients were simulated under steady-state assumptions, then exposed to various adherence scenarios. A modified Metropolis-Hastings algorithm jointly estimated individual pharmacokinetic parameters and dosing patterns by analyzing simulated drug and metabolite concentrations. The probability of taking 0, 1, or 2 tablets per day was inferred, and a posterior adherence probability was derived from the posterior distribution to quantify adherence likelihood. A receiver operating characteristic analysis was used to evaluate diagnostic performance. RESULTS: The combined use of parent and metabolite improved non-adherence detection compared with either alone, particularly for recent missed doses. Trough concentrations outperformed peak concentrations, especially when patients did not compensate with extra doses. CONCLUSIONS: This probabilistic bi-analyte approach enhances non-adherence detection and is adaptable to other pharmacokinetic settings where distinct profiles and low model variability are present.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Chaiben S, Gandia P, Duly-Bouhanick B, et al. Blood Never Lies: The PopPK-Based Lie Detector. Clin Pharmacokinet. 2026. PMID: 42301614. doi:10.1007/s40262-026-01652-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。